Update on the EMA Guidance on Protection of Personal Data & CCI
Recommendation
28/29 April 2026
From QbD to Process Validation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Medicines Agency (EMA) plans to gradually resume clinical data publication from September 2023, having temporarily suspended this activity. Therefore, the EMA has revised and supplemented the previously published documents on the transfer of personal data and commercially confidential information (CCI) through the CTIS. The following documents have been published:
- Updated Guidance document (final version) on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information System (CTIS) version 1.1
- Updated Annex I - Guidance document on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information System (CTIS) version 1.0
- New Annex II - Guidance document on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information system (CTIS). The template applies to Good Clinical Practice (GCP) inspections carried out to category 1 trials (i.e., pharmaceutical development clinical trials, e.g. Bioequivalence Study) where the publication of clinical trial information is delayed by a deferral.
More information is available on EMA´s Support for industry on clinical data publication and Clinical Trials Information System: training and support Websites.
Related GMP News
16.04.2026EMA Guidance on Conducting Clinical Trials during Public Health Emergencies
16.04.2026EMA accelerates Development of Medicines
16.04.2026What are the GMP Requirements for Drug Development?
26.03.2026FDA Guidance on Statistical Methods for Clinical Trials
26.03.2026Final ICH M11 CeSHarP Guideline
24.02.2026Good AI Practice in Drug Development